News

The associate chief of clinical pediatric neurology, director of the pediatric neurophysiology lab, and director at the Adolescent Epilepsy Center at UCLA spoke about therapeutic options for pediatric epilepsy.

With a heavy focus on the need for new treatments in Alzheimer, there remains a need to ensure patients are cared for first and foremost.

M. Scott Perry, MD, spoke about the industry's excitement surrounding the current treatment landscape for pediatric epilepsy.

Novel biomarkers are being explored to help expedite the development of new treatments for Alzheimer disease.

Could the introduction of gene therapies into the Alzheimer space be the beginning of a new era of treatment?

The associate professor of neurology at Mayo Clinic spoke about targeting mitochondria to treat neurologic disorders.

Ensuring patients quality of life is still being attended to is of utmost importance to the director of the Comprehensive Multiple Sclerosis Center at Stony Brook University.

The Medical Director of Neurology and Justin Neurosciences Center at Cook Children's Medical Center spoke about the importance of staying up-to-date and informed about this rapidly changing space.

Practice guidelines for the management of low-level, minimally conscious states resulting from brain injury include recommendations for assessment, treatment protocol, and supportive approaches.

Allogeneic mesenchymal stem cells manufactured by Longeveron are advancing through phase I and II clinical trials.

The chairman of the Department of Genetic Medicine at Weill Cornell Medicine shared his experience with the therapy and its potential in the space.

Memory decline was worse for patients with MCI receiving supportive therapy over behavioral activation.

The assistant professor of neurology and neurosurgery spoke about the need to identify LVO in the field, quickly, to improve care.

The director of the Comprehensive Multiple Sclerosis Center at Stony Brook Neuroscience Institute discussed these needs.

Neurology News Network for the week of September 15, 2018.

The director of the Epilepsy Program at the Banner University Medical Center spoke about the importance of interaction between general neurology and epileptologists.

The monoclonal antibody is now the second member of the CGRP inhibitor class to be approved by the FDA.

The third-generation, small molecule CGRP antagonist is the second Biohaven migraine therapy to reach human clinical development.

Jason Lerner MD, discussed the recently opened Adolescent Epilepsy Center at UCLA, a clinic that offers comprehensive care for teens with epilepsy.

TSC has shown potential to become the first approved therapy for acute stroke, able to be administered in the ambulance.

After its approval in May for pediatric MS, the data displayed its efficacy in comparison to standard therapy.

The director of the Dartmouth Headache Clinic at Dartmouth-Hitchcock Medical Center spoke about the potential of a DHE therapy for acute migraine treatment.

Creativity, a human ability that provides artistic, organizational, and scientific innovation, moves the world forward. Do drugs that alter perception help or hinder that process?

The relationship between disease stage and behavior is important given the strength of the relationship relative to cognition and its negative impact on patients and caregivers.

By the open-label extension’s end, those treated with pitolisant showed a decrease in ESS score by 6.2 from baseline.

The co-director of the UPMC’s Center for Endovascular Therapy spoke about the gains that stroke care has made in the last few years.

The idea of marijuana as a panacea for neurologic conditions has come into play, leading to a need for clarification about the use of CBD for these conditions.

Rachel Salas, MD, a Johns Hopkins Associate Professor, spoke about insomnia, a very individualized disorder, and the need for moving toward precision medicine.